Medixon Drug Interactions

If Medixon tablet is administered concomitantly with antidiabetic drugs, the dosage should be adjusted.
Hepatic Microsomal Enzyme Inducers: Drugs eg, barbiturates, phenytoin and rifampicin which induce hepatic enzymes may increase glucocorticoid metabolism, may require dosage adjustments or the drugs not given concomitantly.
Nonsteroidal Anti-Inflammatory Agents: Concomitant administration of ulcerogenic drugs eg, indomethacin, may increase the risk of gastrointestinal tract ulceration. Aspirin should be given cautiously in patients with hypoprothrombinemia. Although concomitant administration with salicylates does not appear to increase the incidence of gastrointestinal ulceration, the possibility of this effect should be considered.
Anticholinesterase Agents: Interaction between glucocorticoids and anticholinesterase agents eg, ambenonium, neostigmine or pyridostigmine can produce weakness in patients with myasthenia gravis. If possible, anticholinesterase treatment should be discontinued at least 24 hrs before initiation of glucocorticoid therapy.
Vaccines and Toxoids: Because corticosteroids may inhibit antibody response, Medixon may cause a diminished response to toxoids and live or inactivated vaccines.
Potassium-depleting diuretics (eg, thiazides, furosemide, ethacrynic acid) and other drugs that deplete potassium eg, amphotericin B, may enhance the potassium-wasting effect of glucocorticoids. Serum potassium should be closely monitored in patients receiving glucocorticoids and potassium-depleting drugs.